Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.

Competing Interests: Declaration of Competing Interest SCC declares having received honoraria for speaking and advisory role as well as travel arrangements for educational purposes from Brystol-Myers-Squibb. The rest of the authors declare no conflict of interest relevant to the publication of this article.